R (remdisivir) is FDA approved L and B (brilacidin) are not. R barely is of benefit, L and B are likely cures. I expect Gilead to add either L or B or both to R so that it actually would be a cure. Without revenue CYDY or IPIX can't make big gains. I am long on both and thinking long term.